Karina Gravgaard Thomsen

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

Per Pfeiffer, Mette Yilmaz, Sören Möller et al. · The Lancet Oncology · 2020 · 224 citations

Gastrointestinal Oncology, Medicine, Pathology +5

Novel circulating microRNA signature as a potential non‐invasive multi‐marker test in ER‐positive early‐stage breast cancer: A case control study

Annette Raskov Kodahl, Maria Lyng, Harald Binder et al. · Molecular Oncology · 2014 · 185 citations · Full text

The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancer

Karina Gravgaard Thomsen, Maria Lyng, Anne‐Vibeke Lænkholm et al. · Breast Cancer Research and Treatment · 2012 · 96 citations

Breast Oncology, Metastatic Tissue, Breast Cancer +7

Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study

Maria Lyng, Anne‐Vibeke Lænkholm, Rolf Søkilde et al. · PLoS ONE · 2012 · 60 citations · Full text

miR-155, identified as anti-metastatic by global miRNA profiling of a metastasis model, inhibits cancer cell extravasation and colonization<i>in vivo</i>and causes significant signaling alterations

Karina Gravgaard Thomsen, Mikkel G. Terp, Rikke Raaen Lund et al. · Oncotarget · 2015 · 22 citations · Full text

Immunology, Pathology, Cancer Biology +19